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Abstract
Background: Little is known about how genetics and epigenetics interplay in depression. Evidence suggests that
genetic variants may change vulnerability to depression by modulating DNA methylation (DNAm) and non-coding
RNA (ncRNA) levels. Therefore, the aim of the study was to investigate the effect of the genetic variation, previously
identified in the largest genome-wide association study for depression, on proximal DNAm and ncRNA levels.
Results: We performed DNAm quantitative trait locus (meQTL) analysis in two independent cohorts (total n = 435
healthy individuals), testing associations between 102 single-nucleotide polymorphisms (SNPs) and DNAm levels in
whole blood. We identified and replicated 64 SNP-CpG pairs (padj. < 0.05) with meQTL effect. Lower DNAm at
cg02098413 located in the HACE1 promoter conferred by the risk allele (C allele) at rs1933802 was associated with
higher risk for depression (praw = 0.014, DNAm = 2.3%). In 1202 CD14+ cells sorted from blood, DNAm at
cg02088412 positively correlated with HACE1 mRNA expression. Investigation in postmortem brain tissue of adults
diagnosed with major depressive disorder (MDD) indicated 1% higher DNAm at cg02098413 in neurons and lower
HACE1 mRNA expression in CA1 hippocampus of MDD patients compared with healthy controls (p = 0.008 and
0.012, respectively). Expression QTL analysis in blood of 74 adolescent revealed that hsa-miR-3664-5p was associated
with rs7117514 (SHANK2) (padj. = 0.015, mRNA difference = 5.2%). Gene ontology analysis of the miRNA target
genes highlighted implication in neuronal processes.
Conclusions: Collectively, our findings from a multi-tissue (blood and brain) and multi-layered (genetic, epigenetic,
transcriptomic) approach suggest that genetic factors may influence depression by modulating DNAm and miRNA
levels. Alterations at HACE1 and SHANK2 loci imply potential mechanisms, such as oxidative stress in the brain,
underlying depression. Our results deepened the knowledge of molecular mechanisms in depression and suggest
new epigenetic targets that should be further evaluated.
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Introduction
Depression is the leading cause of disability worldwide
[1]. Twin studies have shown that depression has a her-
itability of 30–40% [2], and genome-wide association
studies (GWASs) have uncovered many single nucleo-
tide polymorphisms (SNPs) associated with this condi-
tion [3]. The most recent and largest genome-wide
meta-analysis of depression included 807,533 individuals
and identified 102 such SNPs, 87 of which were repli-
cated in an independent cohort of 1,306,354 individuals
[4]. These SNPs all showed small effect sizes, and their
functional roles remain unknown. The collective profile
of SNPs in each individual forms a genetic background
that confers a degree of predisposition to depression.
Environmental factors interact with this genetic profile
to trigger depression, partly via epigenetic mechanisms,
such as the regulatory action of DNA methylation
(DNAm) and non-coding RNAs (ncRNA). Studying the
intricate relationship between genetic variation, DNA
methylation, and ncRNA expression is therefore import-
ant to understand the molecular mechanisms underpin-
ning susceptibility to depression.
DNAm is strongly involved in neurodevelopmental
processes such as synaptic formation and function [5, 6],
especially during adolescence, and its perturbation can
lead to psychiatric disorders [7]. CpG methylation, a
process characterized by the addition of a methyl group
to the fifth carbon of the cytosine ring, influences the
packing of the DNA and its availability for transcription
factors [8]. Typically, DNAm in gene promoters is asso-
ciated with transcriptional repression while is positively
associated with gene expression when located in gene
bodies [9]. Site-specific DNAm is extensively influenced
by the genetic background [10], age [11], sex [12], and
environmental exposure, such as social stress [13, 14].
ncRNAs such as microRNAs (miRNAs) operate at the
post-transcriptional level to add another layer of gene
expression regulation. Increasing evidence suggests miR-
NAs as key modulators of synaptic plasticity and activity
[15, 16] and as an important mechanism linking external
stimuli to changes in brain function [17].
DNAm and miRNA expression may differ depending
on the genotype at a given SNP, which then may cause
alterations in cell, tissue, and whole-body physiology
underlying depression. Interestingly, previous studies
suggested that genetic and epigenetic variations could
interact [18, 19]. This emphasizes the contribution of
epigenetics to human disease, especially as alterations
may be linked to non-protein-coding, disease-associated
genetic variants from GWAS [20, 21].
In this study, we aimed to investigate genotype-
dependent DNAm and ncRNA levels in depression, by
using a multi-tissue (blood and brain) and multi-layered
(genetics, epigenetics, transcriptomics) approach in
different cohorts. We uncovered associations between
the 102 genetic variants identified in the abovemen-
tioned GWAS and shifts in epigenetics (DNAm and
ncRNA) that play a role in potential mechanisms under-
lying depression. First, we identified and replicated DNA
methylation quantitative trait loci (meQTL) in blood
and brain from two independent cohorts. We used two
additional cohorts to investigate the functional conse-
quences of those DNAm alterations at the gene expres-
sion level. Finally, we addressed association between
genetic variation and ncRNA expression, using a cis-ex-
pression quantitative trait locus (eQTL) approach.
Results
Demographic characteristics of the cohorts
Our workflow is summarized in Fig. 1. Both the 216 ad-
olescents from the discovery cohort and the 219 young
adults from the replication cohort had whole blood
methylome and SNP data available. Adolescents were
15.5 ± 0.63 years old, and 75% of them were female and
26% at high risk for depression, as assessed by the Devel-
opment and Well-Being Assessment (DAWBA) (Table 1).
The participants in the replication cohort were young
adults (23.5 ± 3.3 years old), and 22% of them were fe-
males. All participants of the replication cohort, and
97.2% of the discovery cohort, were free of medication.
Differences between the discovery and replication cohorts
included a difference in age of approximately 8 years and
in sex distribution (75% vs 22% females). Body mass index
(BMI) was comparable between the two cohorts (21.9 ±
3.44 and 23.7 ± 3.03, Supplementary Figure 1). The 22
adults with major depression disorder (MDD) and the 23
matched controls from the NICHD Brain Bank of Devel-
opmental Disorders had similar age and sex distribution
(Table 2).
Expression analysis in blood cells was performed in
1202 adults in the MESA cohort, and the mean age was
60.2 ± 9.45 years old. Information about race and sex
could not be extracted from the variable recoded incorp-
orating race, sex, and study site. The 30 adults from the
EXPHIP cohort had mRNA levels available in two hip-
pocampal regions (CA1 and dentate gyrus) and were
60% males and 83% Caucasians (Table 3).
Association of depression-related genetic risk variants
with proximal DNAm in whole blood
We performed a cis-meQTL analysis in the discovery co-
hort (Table 1), using a dominant genetic model for each
SNP, and controlling for age, sex, and batch. In our co-
hort, the minor allele frequency (MAF) of the 102
GWAS studied SNPs that were in a range similar to
other Caucasian populations [4] (Supplementary Table
1). We identified 91 CpGs associated with 46 SNPs,
forming 91 SNP-CpG pairs spread throughout the
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Fig. 1 Study design and workflow diagram. Using whole blood of the discovery cohort comprising adolescents, meQTL analyses, together with
associations between ncRNA levels and genotype and DNAm and depression scores were performed. The replication cohort comprised 219
adults and 64 previously identified meQTL-CpG pairs were validated in whole blood. The NICHD cohort containing 45 adult brain tissues was
used to analyze the association between the MDD diagnosis and DNAm at the HACE1 gene. A positive relationship between DNAm degree and
RNA expression levels of HACE1 was identified in CD14+ cells, in the MESA cohort. The EXPHIP cohort included 15 MDD-diagnosed and 15
matched controls and helped to identify lower HACE1 mRNA levels in depressed CA1 hippocampal region. The functional relevance of the
findings was investigated using different bioinformatic or molecular biological software tools. DAWBA, Development and Well-Being Assessment;
DNAm, DNA methylation; SNP, single-nucleotide polymorphism; ncRNA, non-coding RNA; meQTL, methylation quantitative trait locus; MDD,
major depressive disorder
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genome (adjusted p value < 0.05, Fig. 2a, Supplementary
Table 1).
We then attempted to replicate our initial 91 SNP-
CpG pairs in an independent cohort. Four of the 91
pairs could not be analyzed as they were excluded in the
preprocessing procedure. DNA levels at the 87
remaining CpGs were linearly regressed against the pre-
viously identified meQTLs-SNPs (dominant genetic
model), covarying for age and sex. In total, 64 SNP-CpG
pairs were replicated in the independent cohort, with
Benjamini-Hochberg (BH)-adjusted p values < 0.05
(Table 4, Supplementary Table 2). All but two of the 64
replicated pairs had a similar DNAm direction for SNP
risk carriers in both discovery and replication cohorts.
Fifty four percent of the 64 replicated CpGs were hypo-
methylated in carriers of the risk allele for depression
(Supplementary Table 2). The rs3823624 SNP within
MAD1L1 was associated with the highest number of
CpG sites (n = 9 CpGs). The risk allele for depression
(the C allele) was associated with lower DNAm at six
CpGs, with the highest effect size at the pair rs3823624-
cg19624444 (6.8% DNAm difference in the discovery co-
hort and 8.6% in the replication cohort between T major
allele carriers and C risk allele carriers).
Lower DNAm at cg02098413 in whole blood is associated
both with depression risk and with the risk allele at
rs1933802 in the HACE1 gene
We next tested whether blood DNAm at the 64 discov-
ered and replicated CpGs was associated with depression
risk in the discovery cohort. DNAm levels were available
for 221 adolescents, who were categorized based on the
DAWBA depression scores as “low-risk” or “high-risk”
for depression. The binary variable was regressed against
the 64 replicated CpGs together with age, sex, and
DNAm batch as covariates (Supplementary Table 3).
Higher DNAm at cg02098413 located upstream of
HECT Domain and Ankyrin Repeat Containing E3
Table 1 Characteristics of the adolescents from the discovery cohort
Low-risk (n = 160) High-risk (n = 56) p value**
Male: Female 47 (19.4):113 (80.6) 6 (13.1):50 (86.9) 0.0089
Age (years) 15.4 ± 0.63 15.6 ± 0.65 0.15
Body mass index (kg/m2) 21.61 ± 3.02 22.83 ± 4.33 0.054
DAWBA level bands*
General band 70 (19.4) 56 (100) 6.03e-14
Panic disorder 9 (5.6) 5 (8.9) 0.00041
Posttraumatic disorder 14 (2.5) 9 (16) 5.44e-6
Separation anxiety disorder 5 (3.1) 6 (10.7) 2.05e-5
Generalized anxiety disorder 30 (18.7) 23 (41.1) 2.11e-7
Social phobia 17 (10.6) 14 (25) 0.016
Obsessive-compulsive disorder 9 (5.6) 6 (10.7) 0.028
Conduct disorder 10 (6.2) 9 (16.1) 7.89e-6
Specific phobia 9 (5.6) 7 (12.5) 0.0072
Variables are shown as mean ± standard deviation or number (percentage)
*All listed DAWBA bands refer to individuals at high-risk (defined by DAWBA bands = 3, 4, or 5) of, e.g., general band, depression, and panic disorder
**Two-tailed Student’s t test for continuous variables and chi-square test for categorical variables (likelihood ratio). Significant p values are written in bold
and italics
Individuals with depression DAWBA band risk scores <15% were considered at low-risk for depression; individuals with depression DAWBA level bands 3 (≈ 15%),
4 (≈ 50%), or 5 (> 70%) were considered at high-risk for depression
DAWBA Development and Well-Being Assessment
Table 2 Characteristics of individuals in NICHD Brain Bank of
Developmental Disorders cohort
MDD (n = 22) Controls (n = 23) p value*
Male:Female 12 (54.5):10 (45.5) 12 (52.2):11 (47.8) 1
Age (years) 33.6 ± 16.4 33.4 ± 16.2 0.95
Variables are shown as mean ± standard deviation or number (percentage).
*Student’s t test for continuous variables and chi-square test for categorical
variables (likelihood ratio)
MDD major depression disorder
Table 3 Characteristics of individuals in the EXPHIP cohort
MDD (n = 15) Controls (n = 15) p value*
Male:female 9 (60):6 (40) 9 (60):6 (40) 1
Age (years) 59.2 ± 16.7 58.4 ± 15.2 0.68
Race (C:AAm) 14 (93.3):1 (6.7) 11 (73.3):4 (26.7) 0.32
Variables are shown as mean ± standard deviation or number (percentage).
*Chi-square test for categorical variables (likelihood ratio)
MDD major depression disorder, C Caucasians, AAm African American
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Ubiquitin Protein Ligase 1 (HACE1) was associated with
lower depression score (praw = 0.014, odds ratio (OR) =
0.23) (Fig. 2b). Lower DNAm at cg02098413 was also as-
sociated with the risk allele at rs1933802, in both the
discovery (Fig. 2c) and replication cohorts (padj. = 0.0029
and 0.0063, respectively) (Supplementary Table 2). Each
risk allele (C allele) was associated with a 1% decrease in
DNAm at cg02098413. The MAF in adolescents at low-
risk for depression was 0.54, compared with 0.42 in
those at high-risk for depression.
DNAm at cg02098413 is positively associated with HACE1
gene expression in whole blood
DNAm levels at cg02098413 and HACE1 mRNA levels
(transcript ID: ILMN_1740217) were investigated in 1202
CD14+ samples. A 15% increase in DNAm at cg02098413
was associated with a one unit change in HACE1 mRNA
expression (p = 0.00060) (Supplementary Figure 2).
Increased DNAm at cg02098413 and reduced expression
of HACE1 in the adult brain are associated with
depression
Exploration of chromatin states of this locus revealed
that cg02098413 is located next to the active chromatin
region in all seven investigated brain regions and periph-
eral blood mononuclear primary cells (PBMC) (Fig. 3).
DNAm level at cg02098413 in blood was positively cor-
related with DNAm in Brodmann area (BA) 10 region
(prefrontal cortex), but not to BA20 or BA7 regions. In
addition, rs1933802 is a meQTL for cg02098413 in brain
(p = 1.97 × 10−05, Spearman r = 0.19). Transcriptome
data across tissues (GTEx) and at a single-cell resolution
Table 4 Validated meQTL-CpG pairs
meQTL SNP Chromosome Associated gene No. of paired CpGs*
rs301799 1 RERE 2
rs1890946 1 NRDC 1
rs72710803 1 AL122019 2
rs7585722 2 RNF103-CHMP3 2
rs4346585 3 SOCS5P3, ZKSCAN7-AS1 3
rs13084037 3 KLHDC8B 2
rs7624336 3 TKT 1
rs6783233 3 LOC101926953 1
rs7685686 4 HTT 5
rs34937911 4 SLC30A9 1
rs60157091 5 KIF2A 1
rs200949 6 HIST1H1B 7
rs7758630 6 LOC107984041 1
rs1933802 6 HACE1--[]--LIN28B 2
rs3823624 7 MAD1L1 9
rs2043539 7 TMEM106B 2
rs7030813 9 PAX5 1
rs2670139 9 DENND1A 1
rs198457 11 - 4
rs7117514 11 SHANK2 1
rs3213572 12 SPPL3 1
rs1343605 13 OLFM4--[] 1
rs4772087 13 STK24 1
rs1045430 14 AREL1 1
rs62091461 18 RAB27B 1
rs7241572 18 KCNG2 6
rs12624433 20 SLC12A5 1
rs5995992 22 RBX1---[]-EP300 3
*Validation analysis was run by applying lm models between the methylation level and genetic dominant model, adjusting for age and sex The Benjamini-
Hochberg multiple-testing adjustment was applied to the p values. A CpG site was paired with the meQTL SNP if the adjusted p value < 0.05
meQTL methylation quantitative trait locus, SNP single nucleotide polymorphism
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in the human analyses indicated that HACE1 gene is
highly expressed in the brain, particularly in neurons,
followed by astrocytes (Supplementary Figure 3).
We investigated the relevance of DNAm at
cg02098416 in the brain of 22 adults with MDD and 23
matched controls from the NICHD Brain Bank of Devel-
opmental Disorders. DNAm was available for both neur-
onal and glial cells, and adjusted for age and sex. DNAm
at cg02098413 in neurons was positively associated with
depression (p = 0.008, difference of 1% between MDD
and controls), and we found the opposite trend in glial
cells (p = 0.072) (Fig. 4a, b).
We next examined HACE1 expression in the postmor-
tem hippocampal tissue of patients diagnosed with
MDD compared with matched controls. CA1 regions
from MDD individuals displayed lower mRNA levels of
HACE1 compared with controls (p = 0.012). No differ-
ence in HACE1 expression was identified in the dentate
gyrus region (p = 0.6).
Four of the 102 SNPs are eQTL for nearby ncRNA
In addition to DNAm, we investigated the link between
depression-related SNPs and expression of nearby
ncRNAs (± 500 kbp window around the SNP locus) in
74 adolescents from the discovery cohort. ncRNA
expression levels were regressed against the SNP, adjust-
ing for sex and age. Out of 229 unique SNP-ncRNA
tested pairs, four were significant (padj. < 0.05, Table 5),
the most significant association being rs7117514-miR-
3664-5p (Fig. 5a).
To infer the biological relevance of miRNA expres-
sion changes, we performed gene ontology (GO) ana-
lysis of the predicted target genes for the identified
miRNAs, hsa-miR-3664-5p, hsa-miR-488-5p, and hsa-
miR-6728-3p. Enriched GO terms associated with
hsa-miR-3664-5p target genes were behavioral fear
and defense response, presynaptic signal transduc-
tions, and presynaptic active zone organization; GO
term related with hsa-miR-6728-3p target genes was
social behavior, synapse organization, locomotory be-
havior, and muscle adaptation to stimulus, learning,
or memory (Fig. 5b). No significant GO terms had
gene set enrichment > 10% coverage for hsa-miR-488-
5p. Pathway analysis indicated neuronal system and
intracellular signaling as potential processes implicat-
ing the target genes (Supplementary Table 2).
Discussion
We addressed the potential mechanisms underlying gen-
etic risk for depression by intersecting several molecular
Fig. 2 a Manhattan plot of the meQTL associations in whole-blood samples of 216 adolescents. The line represents the significance level at
Bonferroni corrected p value of 0.05. b Blood DNAm levels (β values) at cg02098413 within the HACE1 gene in the discovery cohort. Adolescents
with depression DAWBA band risk scores below 15% were defined as “Low-risk”, while individuals with depression DAWBA level bands 3 (≈ 15%),
4 (≈ 50%), or 5 (> 70%) were assigned to the “High-risk” category. c Blood DNAm levels (β values) at cg02098413 within HACE1 gene vs the
presence of the risk allele (C allele) at rs1933802. *p values < 0.05, **p values < 0.005
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layers, namely, epigenetic and transcriptional, with gen-
etic profiles. We investigated the association between
genetic variations and DNAm as well as ncRNA expres-
sion in diverse datasets, including adolescents at high
risk for depression and adults diagnosed with MDD.
Among the replicated meQTLs, DNAm at cg02098413
located in the promoter of HACE1 was associated with
rs1933802. In addition, this CpG in whole blood and
brain was associated with depression in two independent
cohorts. This differential methylation could have a func-
tional impact as HACE1 expression levels were lower in
CA1 hippocampal samples of depressed adults. There-
fore, we showed cumulative evidence for rs1933802 to
play a regulatory role in depression etiology via differen-
tial DNAm at cg02098413. Lastly, two GWAS SNPs
were eQTL for four small ncRNAs implicated in neuro-
biological processes.
Approximately, half of the 102 associated SNPs with
depression were found to be cis-meQTL, indicating that
they may give susceptibility to depression via effects on
local DNAm. We found that the risk allele at rs1933802
was associated with lower DNAm at cg02098413 in
blood. In contrast, the risk allele was associated with
higher DNAm levels in brain tissue. Additionally,
DNAm at cg02098413 in whole blood was associated
with depression risk, and DNAm at cg02098413 in the
brain was associated with MDD. Interestingly, our data
revealed the tissue specificity of genetically dependent
DNAm levels in relation to MDD, i.e., lower DNAm in
whole blood and higher DNAm in the prefrontal cortex.
We hypothesize that rs1933802 exerts tissue- or cell
type-specific effect on proximal DNAm levels, as
meQTLs are coordinated by variation in transcription
factor binding to specific genes, which is tissue-specific
[22, 23]. Moreover, one cannot exclude the possibility of
additional tissue- or cell type-specific mechanisms in-
volved in the observed DNA methylation changes. In
line with this, DNAm levels can vary within tissues,
including across different brain regions [24], and we
identified differential DNAm in neurons specifically, as
opposed to glial cells, of MDD patients. Thus, even
though we found a positive correlation between DNAm
Table 5 Significant SNP-ncRNA pairs after the Bonferroni multiple-testing adjustment
SNP RefGene Position (hg19) ncRNA Host gene Bonferroni-adj. p value % ncRNA mRNA levels difference
rs7117514 SHANK2 11:70544937 hsa-miR-3664-5p SHANK2 0.015 5.2
rs72710803 AL122019 1:177428018 hsa-miR-488-5p ASTN1 0.026 10
rs301799 RERE 1:8489302 hsa-miR-6728-3p ENO1 0.032 − 8.9
rs7659414 – 4:177350956 ENSG00000201516 WDR17 0.037 − 3.9
Linear models with ncRNA expression as outcome and SNP, age, and sex as predictors. The difference in mRNA levels is shown between major allele carriers and
heterozygous and homozygous for minor allele
SNP single nucleotide polymorphism, ncRNA non-coding RNA
Fig. 3 Genomic context of the CpG site associated with the depressive phenotype and genetic variant rs1933802. Genomic positions of RefSeq
genes are displayed in the top part and indicated by arrows. The position of the significant CpG site is highlighted by black lines. Since analyses
were performed based on data obtained in blood, chromatin marks overlapping in brain and blood cells were investigated. Chromatin states of 8
tissues downloaded from the 37/hg19 WashU Epigenome Browser are illustrated. Each functional role of a segment is indicated by a particular
color. BrainAC, brain anterior caudate; BrainCG, brain cingulate gyrus; BrainHIPPO, brain hippocampus; BrainITL, brain inferior temporal lobe;
BrainDPC, brain dorsolateral prefrontal cortex; BrainSN, brain substantia nigra; BrainAG, brain angular gyrus; PBMC, peripheral blood mononuclear
primary cells
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levels in BA10 within the prefrontal cortex and blood,
we cannot assume the direction of the correlation be-
tween blood and the entire prefrontal cortex region.
DNAm differences at cg02098413 may have functional
consequences at the cellular and molecular levels (e.g.,
differential transcriptional effect or splicing across tis-
sues). The positive relationship between DNAm and
HACE1 expression we found in CD14+ cells cannot be
extrapolated to a similar direction in the brain. On the
contrary, the high DNAm and low HACE1 expression
observed in MDD brain, although identified in distinct
brain regions and cohorts, concurs to the conventional
view of anti-correlated promoter DNAm and transcrip-
tional changes. This is supported by the diverse
functions of HACE1 in cellular processes such as
tumorigenesis, oxidative stress response, and neurodeve-
lopmental disorders. Importantly, dysfunctional HACE1
has been implicated in structural and functional brain
defects [25, 26]. Previous findings in Hace1 knock-out
mice showed that HACE1 is thought to modulate react-
ive oxygen species (ROS) via its target protein RAC1
[27]. Our results are in line with the growing body of
evidence highlighting the involvement of ROS in relation
to depression [28, 29] and suicidal behavior [30]. More-
over, oxidative stress, resulting from an altered produc-
tion of oxidant and antioxidant reactions, can negatively
affect dendritic arbors and spines. Our findings suggest
that lower HACE1 expression levels in the CA1
hippocampal region of adults diagnosed with major de-
pression might lead to dendritic damage via increased
ROS. Reduced HACE1 levels might rely, at least partly,
on DNAm as MDD-diagnosed individuals had higher
DNAm levels in prefrontal cortex compared with
matched controls.
In our study, the expression of three miRNAs was as-
sociated with a differential expression of their host
genes. The rs7117514 SNP within SHANK2 was associ-
ated with levels of hsa-miR-3664-5p that is located in
the intronic region of the gene. Recently, hsa-miR-3664-
5p was found to suppress the proliferation of gastric
cancer through its target MTDH [31]. While little is
known about the functional role of this miRNA, espe-
cially in a disease context, previous studies highlighted
the importance of intronic miRNAs as their expression
may be coordinated with the host gene’s expression [32,
33], as well as functional processes involving regulation
of the hosts [34] or genes acting on related pathways
[35, 36]. Hsa-miR-3664-5p host gene SHANK2 encodes
the largest isoform of a family of scaffold proteins and is
found abundantly at the postsynaptic site of excitatory
synapses in the CNS [37]. Accordingly, SHANK2 is
thought to act as an initial “organizer” of the postsynap-
tic density, which further recruits SHANK3. Human
genetic studies have implicated aberrant expression of
SHANK2 in phenotypes such as intellectual disability,
schizophrenia, and bipolar disorders [38–40]. Moreover,
Fig. 4 Methylation levels at cg02098413 (HACE1) in a neuronal cells and b glial cells of MDD diagnosed individuals and controls. *p values < 0.05,
¤p values < 0.1
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SHANK2 and SHANK3 have been shown to be causative
genes for autism spectrum disorders [41, 42], possibly
through the regulation of RAC1 function [43]. Import-
antly, a decrease in SHANK2 protein at hippocampal
CA1 synapses leads to dysregulation of N-methyl-d-as-
partate receptors (NMDARs) in mice [44]. This is of
interest since NMDAR plays a critical role in the fast
synaptic glutamate neurotransmission, and its dysfunc-
tion contributes to the pathophysiology of depression
[45]. A new generation of pharmacological treatments
for depression includes NMDAR antagonists, such as
ketamine [46].
In our study, hsa-miR-6728-3p was differentially
expressed in carriers of the rs301799 allele. This intronic
miRNA is located in ENO1 that has been previously re-
lated to depression and diabetes [47]. Interestingly, GO
analysis of hsa-miR-6728-3p target genes revealed pro-
cesses related to motor behavior, regulation of muscle
adaptation in response to stimulus, and locomotory be-
havior. Major depression entails significant disturbances
Fig. 5 a Hsa-miR-3664-5p expression levels and rs7117514 genotype in blood samples of 74 adolescents. b Gene ontology (GO) categories for
the target genes of the microRNAs hsa-miR-3664-5p and hsa-miR-6728-3p. *p values < 0.05
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in psychomotor function [48], such as slower motor re-
sponse times [49] and decreased overall motor activity
[50]. Two other GO terms relate to social behavior and
learning, supporting the evidence that the genetic
dependent miRNA expression could be involved in the
negative response in social stimuli processing [51] and
memory [52] associated with depression.
Our results are strengthened by our comprehensive
bioinformatics analysis that is integrating multiple lines
of evidence point at a role for HACE1 and SHANK2 in
the pathophyology of depression. We combined five in-
dependent cohorts and multiple online tools to investi-
gate the biological relevance of genetics, DNAm,
ncRNA, and mRNA expression in depression. However,
the eQTL analysis of ncRNA has not been replicated in
an independent cohort. In addition, depression risk in
the discovery cohort was assessed by the self-reported
DAWBA questionnaire, without being validated by a
clinician. The heterogeneous condition of depression is
more likely to be endorsed by more individuals than
those that would meet the diagnostic criteria for MDD.
It should be mentioned that the DAWBA questionnaire
was validated in a Brazilian sample [53]. Another limita-
tion of our study was that age ranges and sex distribu-
tion across cohorts were different. However, while
genetics appears to be especially important in regulating
DNAm levels, other covarying factors were taken into
account in our analyses. Importantly, the statistical
models were corrected for age and sex, enabling us to
adjust for the effect of age and sex on DNAm. Moreover,
meQTLs were shown to be stable over the time [54],
where most of age-related DNAm changes accumulate
faster during the adolescence than in adulthood [55].
Sex differences in DNAm provide a potential biologic
mechanism to explain the increased risk of depression in
females [56]. Therefore, additional studies are required
to further ascertain the findings.
Conclusions
In conclusion, our study explores potential molecular
mechanisms and biological processes underlying causal
genetic variants in depression. We present a genotype-
dependent DNAm at the HACE1 gene that associates
with depression in brain and whole blood across diverse
datasets, specifically adolescents at risk for depression
and adults diagnosed with MDD. Moreover, we found
altered gene expression in neuronal cells of depressed
adults, which may lead to dendrite density alteration.
Furthermore, hsa-miR-3664-5p was differentially
expressed in risk allele carriers of a SNP in SHANK2. Al-
tered expression of miRNA and its host may contribute
to the pathophysiology of depression via dysregulation of
NMDARs. Together, our results underscore DNAm,
ncRNA expression and genetic risk factors as an inter-
play modulating mechanism behind depression.
Methods
Discovery cohort of the meQTL analyses - DNAm, SNP
imputation, ncRNA and depression risk
The discovery cohort of 221 individuals was a sample
from 786 unrelated Swedish adolescents aged 17–19, re-
cruited between 2012 and 2017 in Uppsala, Sweden.
Subjects were followed up approximately 1 year after en-
rollment, with the aim to investigate potential psychi-
atric risk factors in youth. Individuals with any severe
cognitive impairment were excluded. Out of the 221
adolescents, six participants were under medication for
depression. Height, age, and medication intake were self-
reported, but body weight and height were measured
and used for BMI calculation. The risk for depression
was assessed using the DAWBA web-based interview de-
signed for individuals aged 5–17 years to generate
Diagnostic and Statistical Manual of Mental Disorders
IV and International Statistical Classification of Diseases
and Related Health Problems-10 based diagnoses [57].
Percentage of risk for depression was categorized in six
band scores, i.e., 0 (< 0.1%), 1 (≈ 0.5 %), 2 (≈ 3%), 3 (≈
15%), 4 (≈ 50%), and 5 (> 70%). The DAWBA depression
band consists of questions related to the occurrence of
depression symptoms in the last 4 months (e.g., level of
sadness, irritability, sleep activity, wish to die, and to
what extent general mood is affected). Individuals with a
score ≥ 3 are considered at high risk for depression [58].
All 786 were genotyped using the Infinium Global
Screening Array at the SNP&SEQ SciLife Platform at
Uppsala University, interrogating 700,078 genetic vari-
ants. SNPs were imputed as previously described [59],
and all 102 selected SNPs had imputation scores > 0.8.
Blood DNAm profiles of the 221 adolescents were
assessed with the Illumina 450 K methylation Beadchip.
Data preprocessing was performed as described in [20,
58]. It should be noted that the methylomes were pro-
filed at two different time points within a time range of
1 year [20]. This time difference in DNAm assessment at
baseline is further referred to as “batch” and taken into
consideration in the meQTL analyses. We performed a
cis-meQTL analysis of CpG sites within ± 500 kbp of
each SNP.
A subset of participants (n = 74) had available ncRNA
measurements. The RNA measurements were performed
with the Affymetrix® miRNA 4.1 Array Plates, using
120 μl of the prepared biotinylated RNA from each sam-
ple. The arrays were then hybridized, washed, stained,
and scanned with the GeneTitan® Multi-Channel instru-
ment. The raw data were normalized in Expression
Console provided by Affymetrix, using the robust multi-
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array average method [60]. A cis-eQTL analysis ncRNAs
within ± 500 kbp of each SNP was performed.
Replication cohort of the mQTL analyses - DNAm and SNP
imputation
Participants in this study (n = 423) are healthy individ-
uals of white European descent aged 18–34 years, re-
cruited in Uppsala, Sweden. The replication cohort
consisted of a subset of 219 individuals free of medica-
tion for psychiatric disorders, who had available both
genetic and DNAm data in blood. Blood samples were
taken in the fasted state.
All participants were genotyped using the Infinium
Global Screening Array, interrogating 700,078 genetic
variants. Prior to imputation, quality control steps were
performed using Plink 1.9 [61]: samples were excluded
based on genotyping call rate (< 95%), high heterozygos-
ity > 2 standard deviations (SD), and missingness rate >
0.05 (n = 8 samples); probes were removed based on
MAF (< 1%), Hardy-Weinberg equilibrium (HWE) (<
1e-6), missingness rate (> 5%), and strand ambiguous-
ness (n = 219,868 probes). A total of 480,210 genotypes
for 415 individuals were included in the pre-phasing ap-
proach implemented in SHAPEIT version 2.7 (r904) [62]
and then imputed using the IMPUTE2 software (version
2.3.2) [63], using the 1000 Genome Project phase 3 inte-
grated variant set as a reference (release October 2014).
Preprocessing of the DNAm data included background
correction (“noob” method) [64], data normalization (all-
sample mean normalization method) [65], and sample
and probe exclusion. No samples were excluded based
on the detection p < 5e-5. We excluded probes with
missing β values, probes having ≤ 75% of samples with
detection p < 0.01, and probes located on the sex chro-
mosomes. Using the annotation generated by Chen et al.
[66], cross-reactive probes and probes containing SNPs
with minor allele frequency > 1% in European popula-
tions were removed as well. In total, 397,620 probes
remained. Batch effects were corrected with the ComBat
function [67]. All data processing was performed using
R version 3.1.3.
Brain DNAm profiles of MDD-diagnosed individuals and
controls from the NICHD Brain Bank of Developmental
Disorders
We tested associations between the newly discovered
meQTLs and depression in a publicity available, proc-
essed DNAm dataset of 58 postmortem cortical tissues
from 29 individuals with MDD, and 29 age- and sex-
matched controls. In these samples, neuronal and glial
cell proportions were measured by fluorescence acti-
vated cell sorting, and DNAm levels were separately ana-
lyzed in neurons and glia (GSE41826). To avoid
confounding of DNAm signals by ethnicity, only data
from Caucasian individuals were included in further ana-
lyses (n = 22 MDD diagnosed individuals and n = 23
controls) [68].
Whole blood DNAm and mRNA expression from the
Multi-Ethnic Study of Atherosclerosis (MESA)
We investigated the functional relevance of the discov-
ered meQTLs by testing associations between DNAm
levels at the meQTLs and mRNA expression in an open-
access dataset (E-GEOD-56047). Methylomes were pro-
filed with the Illumina 450 K methylation Beadchip and
transcriptomes with the Illumina HumanHT-12 V4.0 ex-
pression Beadchip. Details about DNAm data prepro-
cessing and transcriptome quality control can be found
elsewhere [69]. All 1202 participants had information
available on age (44–83 years old), race/ethnicity, study
site, sex, DNAm/expression chip, and proportions of B-
cells, T-cells, neutrophils, and natural killer cell.
Brain mRNA levels in two hippocampal regions of MDD-
diagnosed and matched controls from EXPHIP
To evaluate differential mRNA expression of target
genes with depression, we compared mRNA expression
levels in 15 patients with MDD with 15 age-, sex-, and
race-matched controls in the dentate gyrus and CA1
subregions of the hippocampus (ArrayExpress accession
E-GEOD-24095). Ten adults diagnosed with MDD were
taking anti-depressants, while the controls were not
under medication treatment. Data was analyzed using
the 48 K human HEEBO whole-genome microarrays and
further followed by normalization using linear-log
normalization to stabilize the variance of low expressing
genes and removal of spatial and intensity related biases,
using the MAANOVA library [70].
Functional annotation of meQTLs
We used data from the Roadmap Epigenomics Project
(WashU Epigenome Browser http://epigenomegateway.
wustl.edu/legacy/, human genome version hg19) to
determine chromatin states at the discovered meQTL in
seven brain tissues (brain angular gyrus (BrainAG), brain
anterior caudate (BrainAC), brain cingulate gyrus
(BrainCG), brain hippocampus (BrainHIPPO), brain
inferior temporal lobe (BrainITL), brain substantia nigra
(BrainSN), brain dorsolateral prefrontal cortex
(BrainDLPC)) and PBMC. For easier visualization, the
18-state model was reduced to five states, i.e., active/
flanking active/bivalent/poised TSS, active/bivalent/genic
enhancer, flanking bivalent TSS/enhancer, active tran-
scription, and repressed Polycomb state.
We used correlated DNAm between blood and three
brain regions (BA10 (prefrontal cortex), BA20 (temporal
cortex), and BA7 (parietal cortex)) in 16 individuals,
using Spearman correlations in the online BECon tool
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https://redgar598.shinyapps.io/BECon/ [71]. More details
about the preprocessing of this DNA methylation dataset
are available in [71]. Moreover, the meQTL relationship
was assessed in the brain using the xQTL server [72].
Single cell RNA-seq profiles from Darmanis et al. [73]
were used to investigate RNA expression levels of candi-
date genes in cell clusters, such as neurons, astrocytes,
microglia, oligodendrocytes, OPC, and endothelial cells.
Expression values were log-transformed and centered
using the mean.
We determined the target genes of the identified miR-
NAs using microT-CDS release 5.0 [74]. GO biological
process categories and Reactome cell signaling pathways
with a gene set enrichment > 10% were explored using
Consensus path [75].
Statistical analyses
We used linear models as implemented in the limma
package [76] to find meQTL in the discovery cohort,
with DNAm levels as the dependent variable and SNP
(dominant genetic model with wild-type coded with “0”
and heterozygous and homozygous for the minor allele
coded with “1”), age, sex, and batch as independent vari-
ables. CpGs were deemed significant at a Bonferroni-
adjusted p value < 0.05.
We used linear regression to find eQTL in the discov-
ery cohort, with ncRNA expression levels as the
dependent variable and SNP dominant model, age, and
sex as independent variables. The Bonferroni multiple-
testing adjustment was considered for each analyzed
SNP.
In an independent replication cohort, linear regres-
sions were applied on the identified CpGs against the
SNP dominant model. Analyses were adjusted for age
and sex. A BH-adjusted p value < 0.05 was considered
significant. In the cohort from NICHD Brain Bank of
Developmental Disorders, DNAm levels of significant
CpG sites were regressed against the yes/no depression
diagnosis, adjusting for age and sex. Analyses were run
separately for neurons and glia cells. Using the MESA
cohort, associations between DNAm and mRNA
expression levels at the associated genes were investi-
gated. DNAm data were firstly regressed against age,
race, study site, gender, methylation chip, and the
sample contamination with non-targeted cells, i.e., non-
monocytes. The resulting residuals were included in lin-
ear regression models as an independent variable, to-
gether with expression values as dependent variables.
Covariates were age, race, study site, gender, expression
chip, and the sample contamination with non-targeted
cells. Expression data of the EXPHIP cohort were ana-
lyzed using a two-sided binomial test, assuming a 0.5
probability threshold.
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